Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05121844 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform

StatusActive, Not Recruiting
PhaseNot applicable
SponsorSignos Inc
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 100000 to 31187
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  2. Enrollment target: 50000 to 100000v3
  3. Phase: Not specified to Not applicablev2 Show 6 more changesShow less
    • Enrollment target: 20000 to 50000
    • Primary completion date: Nov 1, 2024 to Nov 1, 2026
    • Primary endpoints revised (2)
    • Study completion date: Nov 1, 2026 to Nov 1, 2027
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Signos Inc
3 trials monitored
See all monitored trials
Diabetes
5,087 trials monitored
See 222 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity, pre-diabetes and diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the Signos mHealth platform, with associated health benefits.
Trial Details
NCT Number NCT05121844
Lead Sponsor Signos Inc
Conditions
(from sponsor)		 Weight Loss, Metabolic Syndrome, Pre-diabetes, Central Obesity, Glucose Intolerance, Metabolic Glucose Disorders
Related terms Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Syndrome, Obesity, Abdominal, Weight Loss
Enrollment 31,187 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov